1st Order Pharmaceuticals (1OP) is a development-stage pharmaceutical company focused on advancing 1OP-2198, an IND-ready small molecule potassium channel opener (KCNQ2/3), for unmet medical and orphan indications in neurology and neuro-ophthalmology.
We use accepted scientific principles in pharmacokinetic and pharmacodynamic (PK/PD) modeling to enable intelligent drug development strategies that
- Reduces the cost of developing new therapeutics for serious diseases
- Decreases the time to availability of important new medicines for patients
- Improves our understanding of the drug's behavior to reduce the risks associated with drug development and general clinical use.
This website is under development...more info to come